150 related articles for article (PubMed ID: 27732954)
1. Phosphoproteomics reveals ALK promote cell progress via RAS/ JNK pathway in neuroblastoma.
Chen K; Lv F; Xu G; Zhang M; Wu Y; Wu Z
Oncotarget; 2016 Nov; 7(46):75968-75980. PubMed ID: 27732954
[TBL] [Abstract][Full Text] [Related]
2. Phosphoproteomic analysis of anaplastic lymphoma kinase (ALK) downstream signaling pathways identifies signal transducer and activator of transcription 3 as a functional target of activated ALK in neuroblastoma cells.
Sattu K; Hochgräfe F; Wu J; Umapathy G; Schönherr C; Ruuth K; Chand D; Witek B; Fuchs J; Li PK; Hugosson F; Daly RJ; Palmer RH; Hallberg B
FEBS J; 2013 Nov; 280(21):5269-82. PubMed ID: 23889739
[TBL] [Abstract][Full Text] [Related]
3. Integrated proximal proteomics reveals IRS2 as a determinant of cell survival in ALK-driven neuroblastoma.
Emdal KB; Pedersen AK; Bekker-Jensen DB; Lundby A; Claeys S; De Preter K; Speleman F; Francavilla C; Olsen JV
Sci Signal; 2018 Nov; 11(557):. PubMed ID: 30459283
[TBL] [Abstract][Full Text] [Related]
4. Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathways.
Van den Eynden J; Umapathy G; Ashouri A; Cervantes-Madrid D; Szydzik J; Ruuth K; Koster J; Larsson E; Guan J; Palmer RH; Hallberg B
Sci Signal; 2018 Nov; 11(557):. PubMed ID: 30459281
[TBL] [Abstract][Full Text] [Related]
5. Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis.
Wang Y; Wang L; Guan S; Cao W; Wang H; Chen Z; Zhao Y; Yu Y; Zhang H; Pang JC; Huang SL; Akiyama Y; Yang Y; Sun W; Xu X; Shi Y; Zhang H; Kim ES; Muscal JA; Lu F; Yang J
Sci Rep; 2016 Jan; 6():19423. PubMed ID: 26786851
[TBL] [Abstract][Full Text] [Related]
6. A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment.
Shen J; Najafi S; Stäble S; Fabian J; Koeneke E; Kolbinger FR; Wrobel JK; Meder B; Distel M; Heimburg T; Sippl W; Jung M; Peterziel H; Kranz D; Boutros M; Westermann F; Witt O; Oehme I
Cell Death Differ; 2018 Dec; 25(12):2053-2070. PubMed ID: 29515255
[TBL] [Abstract][Full Text] [Related]
7. New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK.
Di Paolo D; Yang D; Pastorino F; Emionite L; Cilli M; Daga A; Destafanis E; Di Fiore A; Piaggio F; Brignole C; Xu X; Liang C; Gibbons J; Ponzoni M; Perri P
Oncotarget; 2015 Oct; 6(30):28774-89. PubMed ID: 26299615
[TBL] [Abstract][Full Text] [Related]
8. Activation of anaplastic lymphoma kinase is responsible for hyperphosphorylation of ShcC in neuroblastoma cell lines.
Miyake I; Hakomori Y; Shinohara A; Gamou T; Saito M; Iwamatsu A; Sakai R
Oncogene; 2002 Aug; 21(38):5823-34. PubMed ID: 12185581
[TBL] [Abstract][Full Text] [Related]
9. Quantitative phosphoproteomic analysis identifies activation of the RET and IGF-1R/IR signaling pathways in neuroblastoma.
DeNardo BD; Holloway MP; Ji Q; Nguyen KT; Cheng Y; Valentine MB; Salomon A; Altura RA
PLoS One; 2013; 8(12):e82513. PubMed ID: 24349301
[TBL] [Abstract][Full Text] [Related]
10. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret FX; Rassidakis GZ
Cancer Res; 2006 Jul; 66(13):6589-97. PubMed ID: 16818631
[TBL] [Abstract][Full Text] [Related]
11. Novel adaptor protein Shf interacts with ALK receptor and negatively regulates its downstream signals in neuroblastoma.
Takagi D; Tatsumi Y; Yokochi T; Takatori A; Ohira M; Kamijo T; Kondo S; Fujii Y; Nakagawara A
Cancer Sci; 2013 May; 104(5):563-72. PubMed ID: 23360421
[TBL] [Abstract][Full Text] [Related]
12. Mutation-Independent Activation of the Anaplastic Lymphoma Kinase in Neuroblastoma.
Regairaz M; Munier F; Sartelet H; Castaing M; Marty V; Renauleaud C; Doux C; Delbé J; Courty J; Fabre M; Ohta S; Vielh P; Michiels S; Valteau-Couanet D; Vassal G
Am J Pathol; 2016 Feb; 186(2):435-45. PubMed ID: 26687816
[TBL] [Abstract][Full Text] [Related]
13. Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.
Krytska K; Ryles HT; Sano R; Raman P; Infarinato NR; Hansel TD; Makena MR; Song MM; Reynolds CP; Mossé YP
Clin Cancer Res; 2016 Feb; 22(4):948-60. PubMed ID: 26438783
[TBL] [Abstract][Full Text] [Related]
14. Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells.
Schönherr C; Ruuth K; Kamaraj S; Wang CL; Yang HL; Combaret V; Djos A; Martinsson T; Christensen JG; Palmer RH; Hallberg B
Oncogene; 2012 Dec; 31(50):5193-200. PubMed ID: 22286764
[TBL] [Abstract][Full Text] [Related]
15. Peptides derived from the dependence receptor ALK are proapoptotic for ALK-positive tumors.
Aubry A; Galiacy S; Ceccato L; Marchand C; Tricoire C; Lopez F; Bremner R; Racaud-Sultan C; Monsarrat B; Malecaze F; Allouche M
Cell Death Dis; 2015 May; 6(5):e1736. PubMed ID: 25950466
[TBL] [Abstract][Full Text] [Related]
16. Integrated phosphoproteomics and transcriptional classifiers reveal hidden RAS signaling dynamics in multiple myeloma.
Lin YT; Way GP; Barwick BG; Mariano MC; Marcoulis M; Ferguson ID; Driessen C; Boise LH; Greene CS; Wiita AP
Blood Adv; 2019 Nov; 3(21):3214-3227. PubMed ID: 31698452
[TBL] [Abstract][Full Text] [Related]
17. Crizotinib-induced antitumour activity in human alveolar rhabdomyosarcoma cells is not solely dependent on ALK and MET inhibition.
Megiorni F; McDowell HP; Camero S; Mannarino O; Ceccarelli S; Paiano M; Losty PD; Pizer B; Shukla R; Pizzuti A; Clerico A; Dominici C
J Exp Clin Cancer Res; 2015 Oct; 34():112. PubMed ID: 26445453
[TBL] [Abstract][Full Text] [Related]
18. Biological role of anaplastic lymphoma kinase in neuroblastoma.
Osajima-Hakomori Y; Miyake I; Ohira M; Nakagawara A; Nakagawa A; Sakai R
Am J Pathol; 2005 Jul; 167(1):213-22. PubMed ID: 15972965
[TBL] [Abstract][Full Text] [Related]
19. Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma.
Pacenta HL; Macy ME
Drug Des Devel Ther; 2018; 12():3549-3561. PubMed ID: 30425456
[TBL] [Abstract][Full Text] [Related]
20. ALK pERKs up MYCN in neuroblastoma.
Lindner S; Henssen A; Astrahantseff K; Schulte JH
Sci Signal; 2014 Oct; 7(349):pe27. PubMed ID: 25351246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]